Childhood respiratory outcomes after neonatal caffeine therapy. Issue 6 (December 2020)

• Record Type: Journal Article
• Authors: Cheong, Jeanie L.Y.; Doyle, Lex W.
• Is Part Of: Seminars in fetal & neonatal medicine. Volume 25:Issue 6(2020)
• Publication Date: 2020-12
• Subjects: Caffeine -- Apnea of prematurity -- Preterm -- Extremely low birthweight -- Bronchopulmonary dysplasia -- Expiratory airflow; Neonatology -- Periodicals; Newborn infants -- Diseases -- Periodicals; Fetus -- Diseases -- Periodicals; 618.9201
• DOI: 10.1016/j.siny.2020.101158
• Languages: English
• ISSNs: 1744-165X

Abstract

Abstract: Caffeine to prevent or treat apnea of prematurity in the newborn period is now standard of care for infants born very preterm. It has both short- and longer-term effects on respiratory health. In the short-term it reduces the duration of assisted ventilation and of oxygen therapy. It also reduces the rate of treatment for a patent ductus arteriosus, and of bronchopulmonary dysplasia. In the longer-term it improves expiratory airflow in childhood, and may have some benefits on respiratory health. Because it has not been used as a neonatal treatment for long enough, it is unknown if neonatal caffeine treatment has any effects on adult expiratory airflow, or on chronic obstructive pulmonary disease in later adult life.